A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

NCT04477291 PHASE1 TERMINATED

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

Details

Lead sponsor	Aptose Biosciences Inc.
Phase	PHASE1
Status	TERMINATED
Enrolment	45
Start date	Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Interventions

• CG-806

Countries

United States